Introduction
Materials and methods
Reagents
Cell lines and treatments
Cell viability and morphology analysis
Cell cycle analysis
Apoptotic cell death assay
Western blotting analysis
Scratch wound healing assay
Invasion assay with collagen
Quantitative real-time PCR (qPCR)
RNA sequencing (RNA-seq) and data analysis
Constructing the protein interaction network
Statistical analysis
Results
SFN decreased the viability and induced morphological changes in human melanoma cells
Sulforaphane induced cell cycle arrest and apoptosis
SFN hampered A375 cell migration and invasion
SFN altered the transcriptome profile of melanoma cells
Time (h) | Gene name and symbol | Fold change |
---|---|---|
2 | Heat shock 70 kDa protein 1A (HSPA1A) | 3.18 |
Heme oxygenase (decycling) 1 (HMOX1) | 2.68 | |
6 | Heme oxygenase (decycling) 1 (HMOX1) | 6.12 |
Heat shock 70 kDa protein 6 (HSP70B’ (HSPA6) | 4.40 | |
NmrA-like family domain containing 1 pseudogene (LOC344887) | 4.39 | |
Aldo-keto reductase family 1, member B10 (aldose reductase) (AKR1B10) | 4.39 | |
Oxidative stress-induced growth inhibitor 1 (OSGIN1) | 4.38 | |
Heat shock 70 kDa protein 1B (HSPA1B) | 4.19 | |
Heat shock 70 kDa protein 1A (HSPA1A) | 4.12 | |
Poly(A)-specific ribonuclease (PARN)-like domain containing 1 (PNLDC1) | 4.01 | |
Tripartite motif family-like 2 (TRIML2) | 3.39 | |
Solute carrier family 7 (anionic amino acid transporter light chain, xc-system), member 11 (SLC7A11) | 3.36 | |
DnaJ (Hsp40) homolog, subfamily B, member 4 (DNAJB4) | 3.33 | |
EP300 interacting inhibitor of differentiation 3 (EID3) | 3.19 | |
Leucine rich repeat containing 37, member A3 (LRRC37A3) | 3.08 | |
SLC7A11 antisense RNA 1 (SLC7A11-AS1) | 3.02 | |
BCL2-associated athanogene 3 (BAG3) | 2.75 | |
Tripartite motif containing 16-like (TRIM16L) | 2.73 | |
Zinc finger, AN1-type domain 2A (ZFAND2A) | 2.64 | |
Thioredoxin reductase 1 (TXNRD1) | 2.54 | |
HtrA serine peptidase 3 (HTRA3) | 2.52 | |
Sulfiredoxin 1 (SRXN1) | 2.33 | |
Sel-1 suppressor of lin-12-like 3 (C. elegans) (SEL1L3) | 2.28 | |
Zinc finger protein 862 (ZNF862) | 2.25 | |
DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1) | 2.11 | |
Tripartite motif containing 16 (TRIM16) | 2.08 | |
MAX dimerization protein 1 (MXD1) | 2.08 | |
Lysine-rich coiled-coil 1 (KRCC1) | 2.07 | |
Heat shock 22 kDa protein 8 (HSPB8) | 1.99 | |
Heat shock 70 kDa protein 1-like (HSPA1L) | 1.91 | |
Glutamate–cysteine ligase, modifier subunit (GCLM) | 1.89 | |
Heat shock 105 kDa/110 kDa protein 1 (HSPH1) | 1.86 | |
Cystathionase (cystathionine gamma-lyase) (CTH) | 1.86 | |
SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans) pseudogene (LOC100506060) | 1.80 | |
Serine/threonine/tyrosine kinase 1 (STYK1) | 1.79 | |
Family with sequence similarity 173, member B (FAM173B) | 1.77 | |
Asparagine synthetase (glutamine-hydrolyzing) (ASNS) | 1.75 | |
Protein phosphatase 1, regulatory subunit 15A (PPP1R15A) | 1.72 | |
ZFP36 ring finger protein (ZFP36) | 1.72 | |
Early growth response 1 (EGR1) | 1.68 | |
ZFP36 ring finger protein (ZFP36) | 1.72 | |
Early growth response 1 (EGR1) | 1.68 | |
Abhydrolase domain containing 4 (ABHD4) | 1.68 | |
Interferon, epsilon (IFNE) | 1.68 | |
Ferritin, light polypeptide (FTL) | 1.62 | |
Dual specificity phosphatase 5 (DUSP5) | 1.62 | |
F-box protein 30 (FBXO30) | 1.62 | |
Aldehyde dehydrogenase 1 family, member L2 (ALDH1L2) | 1.62 | |
Spermidine/spermine N1-acetyltransferase 1 (SAT1) | 1.62 | |
TRAF family member-associated NFKB activator (TANK) | 1.61 | |
Growth factor receptor-bound protein 10 (GRB10) | 1.58 | |
Sequestosome 1 (SQSTM1) | 1.56 | |
CCAAT/enhancer binding protein (C/EBP), gamma (CEBPG) | 1.54 | |
DnaJ (Hsp40) homolog, subfamily A, member 1 (DNAJA1) | 1.54 | |
Nicotinamide nucleotide adenylyltransferase 1 (NMNAT1) | 1.54 | |
ERBB receptor feedback inhibitor 1 (ERRFI1) | 1.51 | |
Histone deacetylase 9 (HDAC9) | 1.48 | |
Sestrin 2 (SESN2) | 1.44 | |
Placental growth factor (PGF) | 1.44 | |
Death effector domain containing 2 (DEDD2) | 1.42 | |
Kelch-like family member 31 (KLHL31) | 1.40 | |
SIX homeobox 4 (SIX4) | 1.40 | |
BTB and CNC homology 1, basic leucine zipper transcription factor 1 (BACH1) | 1.40 | |
Cysteine-rich hydrophobic domain 2 (CHIC2) | 1.39 | |
Zinc finger CCCH-type, antiviral 1 (ZC3HAV1) | 1.37 | |
Cysteine and histidine-rich domain (CHORD) containing 1 (CHORDC1) | 1.30 | |
UDP-glucose 6-dehydrogenase (UGDH) | 1.29 | |
Ligand-dependent nuclear receptor interacting factor 1 (LRIF1) | 1.27 | |
Solute carrier family 4 (sodium bicarbonate cotransporter), member 5 (SLC4A5) | 1.27 | |
Chromosome 16 open reading frame 72 (C16orf72) | 1.25 | |
Glycyl-tRNA synthetase (GARS) | 1.25 | |
Glutamate–cysteine ligase, catalytic subunit (GCLC) | 1.22 | |
NAD-dependent methylene tetrahydrofolate dehydrogenase cyclohydrolase (MTHFD2) | 1.21 | |
Phosphoenolpyruvate carboxykinase 2 (mitochondrial) (PCK2) | 1.21 | |
Phosphoserine aminotransferase 1 (PSAT1) | 1.21 | |
Discoidin domain receptor tyrosine kinase 2 (DDR2) | 1.20 | |
Microtubule-associated protein 1 light chain 3 beta (MAP1LC3B) | 1.18 | |
Glutamic pyruvate transaminase (alanine aminotransferase) 2 (GPT2) | 1.15 | |
DnaJ (Hsp40) homolog, subfamily B, member 6 (DNAJB6) | 1.15 | |
Connective tissue growth factor (CTGF) | 1.14 | |
Phosphoserine phosphatase (PSPH) | 1.14 | |
Heat shock protein 90 kDa alpha (cytosolic), class A member 1 (HSP90AA1) | 1.09 | |
Peroxisome proliferator-activated receptor gamma (PPARG) | −1.16 | |
Carboxypeptidase A4 (CPA4) | −1.19 | |
Tripartite motif containing 65 (TRIM65) | −1.23 | |
Uncharacterized protein KIAA1671 (KIAA1671) | −1.30 | |
Ring finger protein 207 (RNF207) | −1.33 | |
Coagulation factor II (thrombin) receptor (F2R) | −1.34 | |
Lysophosphatidic acid receptor 1 (LPAR1) | −1.37 | |
TBC1 domain family, member 2 (TBC1D2) | −1.38 | |
Ankyrin repeat and LEM domain containing 1 (ANKLE1) | −1.38 | |
Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 (GBGT1) | −1.42 | |
Mesenchyme homeobox 2 (MEOX2) | −1.52 | |
Interleukin 24 (IL24) | −1.57 | |
Mitochondrial rRNA methyltransferase 1 homolog (S. cerevisiae) (MRM1) | −1.61 | |
Keratin-associated protein 2-3 (KRTAP2-3) | −1.63 | |
DDB1 and CUL4-associated factor 16 (DCAF16) | −1.64 | |
Tetraspanin 2 (TSPAN2) | −1.66 | |
Zinc finger, MYM-type 3 (ZMYM3) | −1.66 | |
Transcriptional regulating factor 1 (TRERF1) | −1.67 | |
NUAK family, SNF1-like kinase, 1 (NUAK1) | −1.70 | |
Family with sequence similarity 46, member B (FAM46B) | −1.72 | |
MDS1 and EVI1 complex locus (MECOM) | −1.75 | |
H1 histone family, member 0 (H1F0) | −1.78 | |
Butyrophilin, subfamily 3, member A1 (BTN3A1) | −1.78 | |
ADP-ribosylation factor-like 4C (ARL4C) | −1.79 | |
Rho guanine nucleotide exchange factor (GEF) 4 (ARHGEF4) | −1.85 | |
Uncharacterized LOC730101 (LOC730101) | −1.91 | |
Nance–Horan syndrome (congenital cataracts and dental anomalies) (NHS) | −1.93 | |
Lysophosphatidic acid receptor 3 (LPAR3) | −1.93 | |
Cancer susceptibility candidate 10 (C10orf114) | −2.04 | |
Paraneoplastic Ma antigen 2 (PNMA2) | −2.34 | |
Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (HS3ST1) | −2.38 | |
Cytochrome P450, family 26, subfamily B, polypeptide 1 (CYP26B1) | −2.39 | |
Extracellular leucine-rich repeat and fibronectin type III domain containing 2 (ELFN2) | −2.45 | |
Adenosine A1 receptor (ADORA1) | −2.47 | |
Tensin 1 (TNS1) | −3.00 | |
24 | Poliovirus receptor-related 4 (PVRL4) | 4.64 |
NmrA-like family domain containing 1 pseudogene (LOC344887) | 3.99 | |
Oxidative stress-induced growth inhibitor 1 (OSGIN1) | 3.20 | |
Growth differentiation factor 15 (GDF15) | 3.15 | |
BTG family, member 2 (BTG2) | 2.83 | |
Histone cluster 1, H2bd (HIST1H2BD) | 2.82 | |
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) | 2.67 | |
Heme oxygenase (decycling) 1 (HMOX1) | 2.29 | |
Fas cell surface death receptor (FAS) | 2.28 | |
Ferredoxin reductase (FDXR) | 2.28 | |
Activating transcription factor 3 (ATF3) | 2.23 | |
Tripartite motif containing 16-like (TRIM16L) | 2.22 | |
Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) (ITGB2) | 2.14 | |
KIAA1324 (KIAA1324) | 2.07 | |
SERTA domain containing 1 (SERTAD1) | 2.06 | |
Tripartite motif containing 16 (TRIM16) | 2.02 | |
MDM2 oncogene, E3 ubiquitin protein ligase (MDM2) | 2.01 | |
Pleckstrin homology-like domain, family A, member 3 PHLDA3 | 1.99 | |
Early growth response 1 (EGR1) | 1.92 | |
Ectodysplasin A2 receptor (EDA2R) | 1.91 | |
Tumor necrosis factor (ligand) superfamily, member 9 (TNFSF9) | 1.91 | |
Thioredoxin reductase 1 (TXNRD1) | 1.91 | |
Ferritin, light polypeptide (FTL) | 1.87 | |
Sulfiredoxin 1 (SRXN1) | 1.84 | |
BCL2 binding component 3 (BBC3) | 1.83 | |
Interleukin 11 (IL11) | 1.75 | |
NLR family, pyrin domain containing 1 (NLRP1) | 1.63 | |
Sestrin 1 (SESN1) | 1.62 | |
Phosphatase 1, regulatory subunit 15A (PPP1R15A) | 1.61 | |
Polo-like kinase 3 (PLK3) | 1.51 | |
Histone cluster 1, H2bk (HIST1H2BK) | 1.48 | |
BCL2-associated X protein (BAX) | 1.41 | |
Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein (ID3) | 1.38 | |
Activating transcription factor 5 (ATF5) | 1.36 | |
Sequestosome 1 (SQSTM1) | 1.34 | |
Plexin B2 (PLXNB2) | 1.31 | |
Growth arrest and DNA damage-inducible, alpha (GADD45A) | 1.31 | |
Actin, alpha 2, smooth muscle, aorta (ACTA2) | 1.30 | |
Chromosome 12 open reading frame 5 (C12orf5) | 1.27 | |
p53 and DNA damage regulated 1 (PDRG1) | 1.25 | |
Glucose-6-phosphate dehydrogenase (G6PD) | 1.24 | |
Glypican 1 (GPC1) | 1.22 | |
Four-and-a-half LIM domains 2 (FHL2) | 1.22 | |
Clusterin (CLU) | 1.21 | |
Tumor necrosis factor receptor superfamily, member 12A (TNFRSF12A) | 1.20 | |
Growth arrest and DNA damage-inducible, beta (GADD45B) | 1.19 | |
Glutamate–cysteine ligase, modifier subunit (GCLM) | 1.19 | |
TP53 regulated inhibitor of apoptosis 1 (TRIAP1) | 1.15 | |
Ribosomal protein S27-like (RPS27L) | 1.13 | |
Peptidylprolyl isomerase F (PPIF) | 1.11 | |
Zinc finger, AN1-type domain 2A (ZFAND2A) | 1.09 | |
Damage-specific DNA binding protein 2, 48 kDa (DDB2) | 1.09 | |
tRNA methyltransferase 61 homolog A (S. cerevisiae) (TRMT61A) | 1.09 | |
Apoptosis enhancing nuclease (AEN) | 1.09 | |
Heat shock 105 kDa/110 kDa protein 1 (HSPH1) | 1.08 | |
Polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa (POLR2A) | 1.05 | |
Ubiquitin-conjugating enzyme E2S (UBE2S) | 1.03 | |
Tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B) | 1.02 | |
Cathepsin L (CTSL1) | 1.02 | |
Phosphoprotein enriched in astrocytes 15 (PEA15) | 0.98 | |
BCL2-associated athanogene 3 (BAG3) | 0.97 | |
Partner of NOB1 homolog (S. cerevisiae) (PNO1) | 0.94 | |
Interleukin 7 receptor (IL7R) | 0.92 | |
Cysteine and histidine-rich domain (CHORD) containing 1 (CHORDC1) | 0.91 | |
Aminolevulinate, delta-, synthase 1 (ALAS1) | 0.91 | |
Biogenesis of lysosomal organelles complex-1, subunit 2 (BLOC1S2) | 0.86 | |
Shwachman–Bodian–Diamond syndrome pseudogene 1 (SBDSP1) | 0.84 | |
DnaJ (Hsp40) homolog, subfamily A, member 1 (DNAJA1) | 0.80 | |
CDC28 protein kinase regulatory subunit 2 (CKS2) | 0.77 | |
Superoxide dismutase 1, soluble (SOD1) | 0.77 | |
Translocase of inner mitochondrial membrane 17 homolog A (yeast) (TIMM17A) | 0.75 | |
WD repeat domain 43 (WDR43) | 0.75 | |
EPH receptor A2 (EPHA2) | 0.72 | |
Catalase (CAT) | −0.87 | |
Adducin 3 (gamma) (ADD3) | −0.88 | |
Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1) | −0.89 | |
Tumor necrosis factor receptor superfamily, member 21 (TNFRSF21) | −0.91 | |
Sp1 transcription factor (SP1) | −0.91 | |
Neuronal PAS domain protein 2 (NPAS2) | −0.92 | |
Guanine nucleotide binding protein (G protein), gamma 4 (GNG4) | −0.95 | |
Pleckstrin homology-like domain, family A, member 1 PHLDA1 | −0.97 | |
Plasminogen activator, tissue (PLAT) | −1.02 | |
CD9 molecule (CD9) | −1.02 | |
Isocitrate dehydrogenase 1 (NADP+), soluble (IDH1) | −1.04 | |
Eyes absent homolog 4 (Drosophila) (EYA4) | −1.06 | |
Transducin (beta)-like 1X-linked (TBL1X) | −1.07 | |
Anoctamin 1, calcium activated chloride channel (ANO19) | −1.07 | |
Absent in melanoma 1 (AIM1) | −1.09 | |
Aldehyde dehydrogenase 1 family, member A3 (ALDH1A3) | −1.27 | |
Ras association (RalGDS/AF-6) domain family (N-terminal) member 8 (RASSF8) | −1.28 | |
Sterol regulatory element binding transcription factor 1 (SREBF1) | −1.31 | |
DNA damage-inducible transcript 4 (DDIT4) | −1.32 | |
Ankyrin repeat and SOCS box containing 9 (ASB9) | −1.37 | |
Solute carrier family 1 (SLC1A4) | −1.38 | |
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) | −1.39 | |
Insulin-like growth factor binding protein 3 (IGFBP3) | −1.45 | |
Domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C (SEMA3C) | −1.46 | |
Calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1) | −1.55 | |
Kinesin family member 21B (KIF21B) | −1.56 | |
Insulin-induced gene 1 (INSIG1) | −1.56 | |
Apolipoprotein L, 6 (APOL6) | −1.57 | |
Protein-coupled receptor 110 (GPR110) | −1.59 | |
Homeobox B9 (HOXB9) | −1.70 | |
Neuronal regeneration related protein (NREP) | −1.78 | |
Sushi domain containing 2 (SUSD2) | −1.90 | |
Cystathionine-beta-synthase (CBS) | −2.04 | |
Follistatin (FST) | −2.08 | |
Interleukin 17 receptor D (IL17RD) | −2.20 | |
Integrin, beta 4 (ITGB4) | −2.32 | |
48 | Phosphatidic acid phosphatase type 2 domain containing 1A (PPAPDC1A) | 3.40 |
Cartilage intermediate layer protein 2 (CILP2) | 3.32 | |
Tumor protein p53 inducible nuclear protein 1 (TP53INP1) | 2.39 | |
Patched domain containing 4 (PTCHD4) | 2.11 | |
Class II, major histocompatibility complex, transactivator (CIITA) | 2.02 | |
Kynureninase (KYNU) | 1.83 | |
Ectodermal-neural cortex 1 (with BTB domain) (ENC1) | 1.82 | |
CD55 molecule, decay accelerating factor for complement (Cromer blood group) (CD55) | 1.81 | |
Fas cell surface death receptor (FAS) | 1.71 | |
Sestrin 2 (SESN2) | 1.61 | |
Glucose-6-phosphate dehydrogenase (G6PD) | 1.54 | |
TOX high mobility group box family member 2 (TOX2) | −1.78 | |
ABI family, member 3 (NESH) binding protein (ABI3BP) | −2.63 | |
ADAMTS-like 3 (ADAMTSL3) | −3.44 |
GO category | GO_ID | GO_ID number of genes in the category |
p value |
---|---|---|---|
Biological process
| |||
Response to stress | GO:0006950 | 86 | 2.43e−12 |
Apoptotic process | GO:0006915 | 57 | 3.44e−11 |
Programmed cell death | GO:0012501 | 57 | 3.44e−11 |
Death | GO:0016265 | 60 | 3.44e−11 |
Cell death | GO:0008219 | 60 | 3.44e−11 |
Response to topologically incorrect protein | GO:0035966 | 16 | 9.47e−09 |
Response to unfolded protein | GO:0006986 | 15 | 3.87e−08 |
Regulation of programmed cell death | GO:0043067 | 43 | 4.39e−08 |
Regulation of cell death | GO:0010941 | 43 | 8.30e−08 |
Regulation of apoptotic process | GO:0042981 | 42 | 9.08e−08 |
Response to stimulus | GO:0050896 | 129 | 9.47e−08 |
Cellular response to stress | GO:0033554 | 42 | 2.99e−07 |
Response to organic substance | GO:0010033 | 54 | 4.43e−07 |
Response to chemical stimulus | GO:0042221 | 69 | 1.38e−06 |
Positive regulation of biological process | GO:0048518 | 75 | 2.99e−06 |
Negative regulation of cellular process | GO:0048523 | 68 | 7.14e−06 |
Positive regulation of cellular process | GO:0048522 | 72 | 8.82e−06 |
Negative regulation of biological process | GO:0048519 | 71 | 1.94e−05 |
Execution phase of apoptosis | GO:0097194 | 15 | 2.86e−05 |
Regulation of execution phase of apoptosis | GO:1900117 | 13 | 2.99e−05 |
Apoptotic signalling pathway | GO:0097190 | 13 | 2.99e−05 |
Cellular response to stimulus | GO:0051716 | 98 | 3.49e−05 |
Response to abiotic stimulus | GO:0009628 | 29 | 4.88e−05 |
Intrinsic apoptotic signalling pathway | GO:0097193 | 10 | 9.05e−05 |
Positive regulation of metabolic process | GO:0009893 | 50 | 0.0001 |
Neuron death | GO:0070997 | 12 | 0.0001 |
Regulation of response to stimulus | GO:0048583 | 55 | 0.0001 |
Glutathione metabolic process | GO:0006749 | 7 | 0.0001 |
Serine family amino acid metabolic process | GO:0009069 | 6 | 0.0001 |
Cysteine metabolic process | GO:0006534 | 4 | 0.0001 |
Regulation of protein metabolic process | GO:0051246 | 39 | 0.0002 |
Neuron apoptotic process | GO:0051402 | 11 | 0.0002 |
Homeostasis of number of cells | GO:0048872 | 12 | 0.0002 |
Signal transduction | GO:0007165 | 85 | 0.0002 |
Regulation of metabolic process | GO:0019222 | 90 | 0.0003 |
Positive regulation of cell death | GO:0010942 | 19 | 0.0003 |
Response to oxygen levels | GO:0070482 | 14 | 0.0004 |
Regulation of signal transduction | GO:0009966 | 44 | 0.0005 |
Positive regulation of cellular metabolic process | GO:0031325 | 46 | 0.0006 |
Molecular function
| |||
Protein binding | GO:0005515 | 135 | 6.97e−08 |
Protein dimerization activity | GO:0046983 | 31 | 0.0001 |
Cofactor binding | GO:0048037 | 15 | 0.0001 |
Binding | GO:0005488 | 170 | 0.0005 |
Identical protein binding | GO:0042802 | 27 | 0.0007 |
Vitamin B6 binding | GO:0070279 | 6 | 0.0028 |
Pyridoxal phosphate binding | GO:0030170 | 6 | 0.0028 |
Glutamate–cysteine ligase activity | GO:0004357 | 2 | 0.0065 |
Cellular component
| |||
Ferritin complex | GO:0070288 | 2 | 0.0116 |
Intracellular ferritin complex | GO:0008043 | 2 | 0.0116 |
Glutamate–cysteine ligase complex | GO:0017109 | 2 | 0.0116 |
Cytosol | GO:0005829 | 46 | 0.0217 |
Intracellular organelle lumen | GO:0070013 | 57 | 0.0373 |
Organelle lumen | GO:0043233 | 58 | 0.0373 |
Membrane-enclosed lumen | GO:0031974 | 58 | 0.0373 |
Nucleus | GO:0005634 | 88 | 0.0544 |
Nuclear part | GO:0044428 | 52 | 0.0696 |
Nuclear lumen | GO:0031981 | 47 | 0.0818 |